Placenta accreta is a complication that is rising in incidence. The reported experience of methotrexate treatment in the conservative management of placenta accreta is scant. Three cases of placenta accreta managed with methotrexate are presented. Case 1: A woman had an antenatal diagnosis of placenta percreta. A successful manual placental removal occurred on post-cesarean day 16. Case 2: A woman had retention of a placenta accreta after a term vaginal delivery. Successful dilation and curettage were performed on postpartum day 37. Case 3: A woman had an antenatal diagnosis of placenta previa-percreta with bladder invasion. A simple hysterectomy was performed on post-cesarean day 46. Conservative management and methotrexate treatment resulted in uterine preservation in two of our three patients; however, this treatment did not prevent significant delayed hemorrhage. In view of the rapid resolution of vascular invasion of the bladder, methotrexate may have an important role in the management of placenta percreta with bladder invasion. The utility of methotrexate treatment with the conservative management of placenta accreta requires further evaluation.
Placenta accreta is an abnormal adherence of placental villi to uterine myometrium. Placenta accreta is now the most common cause of emergency postpartum hysterectomy. 1 Leaphart et al. 2 reported a catastrophic hemorrhage during a scheduled cesarean hysterectomy for placenta percreta with bladder invasion requiring 56 U of packed red blood cells despite ideal multidisciplinary perioperative management in a regional trauma center. Such reports, together with the advances in transfusion services and the development of potent antibiotics, have renewed interest in delayed and nonsurgical management of placenta accreta. Arulkumaran et al. 3 reported the first use of methotrexate for the treatment of placenta accreta. The known effect of methotrexate on reducing placental vascularity, resulting in placental necrosis, and the considerable morbidity and mortality of surgical management of placenta accreta, provided the justification for attempting medical treatment of the retained placenta. A MEDLINE search from 1966 to 1999 (keywords: placenta accreta, methotrexate, retained placenta, medical treatment) yielded only six other reports of methotrexate management of accreta. 4 -9 Of the two reports representing an American experience, 6 ,7 the authors offer contradictory conclusions regarding conservative management and methotrexate treatment for retained placenta accreta. One case of placenta accreta, one case of placenta percreta, and one case of placenta percreta with bladder involvement, all managed with methotrexate, are presented here. All patients were offered and agreed to methotrexate courses as adjunctive treatment to conservative management on a case by case basis by the admitting attending perinatologist. All patients signed an informed consent after clearly understanding the toxicity risks and the uncertain efficacy of methotrexate treatment for the management of retained placenta accreta. The particular methotrexate regimens were selected at the discretion of the individual attending perinatologists. Postpartum management for all patients included a plan for hospitalized observation followed by outpatient follow-up if stable. Patients were followed with weekly sonography and ␤-human chorionic gonadotrophin (BhCG) serum tests to assess placental volume and declining placental function. A weekly physical examination, once the patient had been discharged from the hospital, was also performed to assess for development of endometritis or hemorrhage.
CASE PRESENTATIONS Case 1
A 36-year-old gravida 5, para 4004 was admitted at 32 and 5/7 weeks' gestation; she had been transferred from an outlying institution after an episode of painless vaginal bleeding. Her obstetric history included an uncomplicated term vaginal delivery followed by three low transverse cesarean sections. The prenatal course was significant for a low maternal serum ␣-fetoprotein and a normal 46XY fetal karyotype by amniocentesis. Sonography at 24 weeks' gestation revealed a central placenta previa.
On admission, sonography revealed a placenta previa with turbulent placental blood flow extending into the surrounding uterine myometrium with preservation of the uterine-bladder interface consistent with placenta percreta without bladder involvement. Admission hematocrit was 35.5%. The patient was given a course of betamethasone and remained under hospital observation in stable condition. In
view of the likelihood of substantial hemorrhage from immediate operative management of placenta previa-percreta and the possibility of bladder invasion, a preoperative plan for nonremoval of the placenta was agreed on by the patient and perinatal team. An amniocentesis to determine fetal lung maturity at 34 and 2/7 weeks' gestation was deemed immature, and the patient was given a second course of betamethasone. At 35 and 4/7 weeks' gestation, the patient underwent a scheduled cesarean section with a preoperative plan for medical therapy without placental removal. A classical uterine incision, to avoid the placenta, was performed with delivery of an infant boy with Apgar scores of 9 at both 1 and 5 minutes. No cleavage of the placental plane was identified intraoperatively, which is consistent with the diagnosis of accreta, and no attempt was made to deliver the placenta. Methotrexate (50 mg) was injected into the umbilical vein in an attempt to maximize local delivery of the drug and minimize systemic toxicity. The uterus was closed and the remainder of the operation was uneventful. The estimated operative blood loss was 600 ml. The postoperative course was marked by daily passage of placental tissue and slight vaginal bleeding. A BhCG value of 3902 mIU/ml was obtained on postoperative day 2 and fell to 781 mIU/ml by postoperative day 15. An intramuscular dose of 50 mg of methotrexate was given on postoperative day 3. Thereafter, the patient received weekly methotrexate (50 mg) injections for two additional doses. The patient remained afebrile without evidence of endometritis. A complete blood cell count revealed a hematocrit of 32.0% on postoperative day 8. Weekly ultrasonography revealed a cessation of placental blood flow and a progressive reduction in placental volume. On postoperative day 16, the patient had heavy bleeding vaginally and was taken to the operating room for an attempt at manual placental removal under general anesthesia. Preoperative complete blood cell count revealed a white blood cell count (WBC) of 11.8 k/mm 3 and a hematocrit of 29.6%. The placenta was removed completely with an estimated blood loss of 2000 ml. A uterine packing was placed for 24 hours, and the patient was transfused 4 U of packed red blood cells and 2 U of fresh frozen plasma intraoperatively. In the 48 hours after the manual placental removal, the patient required an additional 6 U of packed red blood cells and 2 U of fresh frozen plasma. Uterine hemorrhage stopped, and sonography revealed a normal postpartum uterine cavity. The hematocrit was stable at 22% on discharge 4 days after the manual removal.
Case 2
A 29-year-old gravida 1, para 0 was admitted as a transfer from an outlying hospital after a term vaginal delivery complicated by retained placenta and failed manual placental removal. The patient denied prior pregnancies or uterine surgery. Her prenatal course was uneventful, with a normal maternal serum ␣-fetoprotein result. On admission, sonography was consistent with placenta accreta with nonvisualization of the hypoechoic zone at the placental interface. Placental removal was not attempted. Serum BhCG was 6270 mIU/ ml. At the discretion of the attending perinatologist, a regimen of methotrexate (50 mg) administered intramuscularly every other day for a total of three doses was decided on. On postpartum day 6, the patient was discharged with a normal WBC count and a hematocrit of 30%. Serial sonography demonstrated no placental blood flow by postpartum day 12, and progressive reduction in placental volume thereafter. A serum BhCG on postpartum day 27 was 330 mIU/ml. On postpartum day 37, the patient was readmitted with complaints of nightly fevers and an episode heavy vaginal bleeding accompanied with syncope. Vital signs included a blood pressure of 110/60 mm Hg, heart rate of 90 beats per minute, and oral temperature of 104.9°F. The abdominal examination was nontender. A pelvic examination revealed no active bleeding with a nontender uterus 8 to 10 weeks in size. She had a WBC count of 18.4 k/mm 3 and a hematocrit of 18.8%. Despite an absence of typical signs of infection, ampicillin, gentamicin, and flagyl were started for presumptive endometritis. The patient was transfused 3 U of packed red blood cells preoperatively. Dilation and curettage were performed with complete removal of the placenta and estimated blood loss of 800 ml. Immediately after the dilation and curettage, an additional 2 U of packed red blood cells were given. The postoperative WBC count was 11.0 k/mm 3 , and the hematocrit stabilized at 29.4%. The patient became afebrile immediately after uterine evacuation and was discharged on the following day in good condition.
Case 3
A 33-year-old gravida 2, para 1001 was admitted at 27 and 5/7 weeks' gestation; she was transferred from an outlying institution for vaginal bleeding with placenta previa. Her obstetric history included a prior low transverse cesarean section for breech presentation at term. The prenatal course was significant for an elevated maternal serum ␣-fetoprotein of 3.7 multiples of the median and normal fetal sonographic anatomy with an anterior placenta previa.
On admission, sonography revealed disruption of the echogenic interface between the maternal uterine serosa and bladder with turbulent flow extending into the bladder wall indicative of placenta percreta with invasion of the bladder. The patient remained hospitalized in stable condition for observation and weekly betamethasone treatments. At 34 and 4/7 weeks' gestation, an episode of vaginal bleeding prompted a cesarean delivery. A cystoscopy was performed immediately before the cesarean section by a urology consultant confirming invasion of placental vessels into the bladder wall. At laparotomy, a blush of vessels was seen occupying the utero-vesical fold. A classic uterine incision was made, with delivery of an infant boy with Apgar scores of 8 and 9 at 1 and 5 minutes, respectively. No attempt at placental removal was made. Methotrexate (50 mg) was injected into the umbilical vein, and the uterus was closed uneventfully. The postoperative course was normal. An intramuscular dose of 50 mg of methotrexate was given on postoperative days 7, 14, 21, and 28 with intervening weekly folinic acid rescue at the discretion of the attending perinatologist. A serum BhCG was 11,412 mIU/ml. On postoperative day 30, the patient was discharged from the hospital in stable condition with a hematocrit of 35%. On postoperative day 46, the patient was readmitted with uterine hemorrhage. She had a WBC count of 9.4 k/mm 3 , a hematocrit of 27.6%, and a serum BhCG of 165 mIU/ml on admission. The patient was taken to the operating room where an attempt at manual placental removal was unsuccessful. A total abdominal hysterectomy was performed. The bladder flap was free of placental vessels and was easily dissected. An estimated blood loss of 3000 ml required replacement with 4 U of packed red blood cells and 2 U of fresh frozen plasma intraoperatively. In addition, the patient received 4 U of packed red blood cells postoperatively. The patient was discharged on the fourth day posthysterectomy with a stable hematocrit of 26.5%. Histopathologic examination of the placenta confirmed placenta percreta.
DISCUSSION
Surgical management of placenta accreta with immediate hysterectomy can be associated with life-threatening hemorrhage and precludes future childbirth. Several reports of conservative management suggest that nonsurgical treatment of placenta accreta is an appropriate consideration for selected patients. 10 -12 Only two case reports describe the American experience of methotrexate administration as an adjunct to conservative management of placenta accreta. Legro et al. 6 administered methotrexate for retained placenta percreta after a vaginal delivery at 35 weeks' gestation. A normal uterine cavity was found 8 weeks after delivery, and the patient had a subsequent normal pregnancy. Jaffe et al. 7 reported the first case of methotrexate treatment after cesarean section with retained placenta percreta and bladder invasion. Hemorrhage ensued at suction curettage 7 weeks after delivery, requiring hysterectomy, partial bladder resection, and bilateral ureteral reimplantation.
The incidence of accreta is known to rise with increasing numbers of cesarean deliveries and uterine curettages. 13 The major risk factor for accreta is the presence of a placenta previa with a previous cesarean scar, a situation requiring hysterectomy in ϳ66% of cases. 14 In our series, two of the three patients had placenta previa in association with a history of prior cesarean section. However, case 2 had accreta occurring with her first pregnancy, thus supporting the recommendation of routine evaluation of accreta risk on every sonographic study obtained.
In our series, significant delayed hemorrhage occurred in all cases despite conservative management and methotrexate treatment. However, unlike the catastrophic hemorrhages reported accompanying immediate surgical management of placenta percreta, 2 the blood product replacement required in all of our cases was well within the capability of the institutional transfusion services.
Historically, endometritis is a feared complication of retained placenta. One of three patients (case 2) was diagnosed with endometritis, and this patient had atypical physical findings presenting on postpartum day 37. An infectious sequela thus is not an obligate attendant of conservative management, and indeed may be temporally remote to delivery when it does occur.
Although progressive reduction of maternal serum BhCG values and residual placental volume occurred in all three cases, the relative contributions of methotrexate versus conservative management in these reductions are not discernible from our cases.
In the third case, placental invasion of the bladder was judged by both obstetric and urologic consultants to require bladder resection and ureteric reimplantation were immediate cesarean-hysterectomy to have been performed. It is of interest that complete resolution of the vascular involvement of the bladder after methotrexate treatment allowed a simple hysterectomy to be performed 46 days after the delivery date.
Due to the individual management of these cases, no uniform regimen of methotrexate was adhered to. However, despite the differing methotrexate courses, none of the patients manifested drug toxicity. The safety of methotrexate treatment of retained gestational tissues, although not without exception, is generally supported in the literature. 15, 16 Our cases demonstrate that immediate hemorrhage can be avoided by not attempting any manipulation of the placenta. This underscores the importance of sonographic diagnosis of placenta accreta, preferably antenatally or at time of vaginal delivery when a placenta is not spontaneously expelled. Diagnosis of placenta accreta and avoidance of attempts to deliver the placenta allow an opportunity for multidisciplinary consultation as well as transfer to tertiary care centers with comprehensive transfusion services.
Although two of three patients in our series had uterine preservation with conservative management and methotrexate treatment, in view of the significant risk of delayed bleeding, immediate hysterectomy should be viewed as the safest management option when placental invasion is contained within the uterus. Methotrexate treatment may thus be considered for those patients adamant about future childbearing or avoiding hysterectomy. However, in view of the resolution of bladder involvement in case 2 and the catastrophic hemorrhage typically attendant to cesarean-hysterectomies requiring bladder resection, patients with bladder invasion by a placenta percreta may be the best candidates for consideration of methotrexate treatment. The utility of methotrexate treatment with the conservative management of placenta accreta requires further evaluation.
